• Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Investors
  • Contact Us
Hillstream
  • Home
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
  • Investors
  • Contact Us
    Loading posts...
  • Hillstream BioPharma Announces Pricing of Initial Public Offering

    Hillstream BioPharma Announces Pricing of Initial Public Offering January 11th, 2022 BRIDGEWATER, NJ / ACCESSWIRE / January 11, 2022 / Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream", the "Company"), a biotechnology company developing novel therapeutic…
    January 11, 2022
    Announcement
  • Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright

    Hillstream Selected to Present at the 2021 BioConnect Virtual Conference Hosted by H.C. Wainwright January 11th, 2021 Bridgewater, New Jersey - Hillstream BioPharma, Inc. (“Hillstream”), a clinical- stage biotechnology company leveraging its…
    January 11, 2021
    Announcement
  • Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma

    Hillstream BioPharma’s HSB-888 Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Osteosarcoma November 23rd, 2020 Osteosarcoma remains the most common primary pediatric bone malignancy mostly occurring in adolescents for which…
    November 23, 2020
    Announcement
  • Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board

    Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board November 18th, 2020 Hillstream BioPharma Announces Richard M. Stone, MD as New Member to Scientific Advisory Board Expertise…
    November 18, 2020
    Announcement
  • Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML

    Hillstream BioPharma Announces Renewal of CRADA with National Center for Advancing Translational Sciences for Use of Quatramer™ Technology with HDAC6-PI3Kδ Dual Inhibitor for AML November 2nd, 2020 Hillstream BioPharma Announces Renewal of…
    November 2, 2020
    Announcement
  • Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

    Hillstream BioPharma Completes Pre-IND Review with FDA on HSB-1216 for Small Cell Lung Cancer (SCLC) October 1st, 2020  Bridgewater, New Jersey, October 21, 2020 – Hillstream BioPharma Inc. (“Hillstream”, the “Company”), a…
    October 21, 2020
    Announcement
  • Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020

    HillstreaHillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and Orphan Products Breakthrough Summit 2020 October 1st, 2020 Hillstream BioPharma to Participate in Panel During 2020 NORD Rare Diseases and…
    October 5, 2020
    Announcement
  • Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference

    Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference October 1st, 2020 Hillstream BioPharma to Present at the Tenth Annual BioNJ BioPartnering Virtual Conference Bridgewater, New Jersey, October 1,…
    October 1, 2020
    Announcement
  • Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020

    Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020 August 17th, 2020 Hillstream BioPharma to Present at the World Orphan Drug Conference USA 2020  Chester, New Jersey, August 17,…
    August 17, 2020
    Announcement
  • Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II

    Hillstream BioPharma Presentations at 2020 AACR Virtual Annual Meeting II FEBRUARY 10, 2020 Abstracts highlight data from HSB-1216 (Salinomycin QUATRAMER™) in small cell lung cancer and triple negative breast cancer Chester, NJ…
    May 19, 2020
    Announcement
Show more All posts are shown

Recent Posts

  • Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.
  • Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
  • Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
  • Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
  • Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

Address:

245 Main St., Ste. 204
Chester, NJ

Tel: +1 (917) 214-3514
Mail: info@hillstreambio.com
Hillstream Biopharma

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807

Tel: 1-908-955-3140
eMail: info@tharimmune.com

Latest News

  • Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023
  • Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference September 21, 2023
  • Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis September 11, 2023

© Copyright 2023. Tharimmune, Inc. All Rights Reserved

Terms of use | Privacy Policy

Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}